Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Jung, Ki Sun | - |
dc.contributor.author | Kim, Hae Su | - |
dc.contributor.author | Lee, Ji Yun | - |
dc.contributor.author | Lim, Sung Hee | - |
dc.contributor.author | Kim, Moonjin | - |
dc.contributor.author | Jung, Hyun Ae | - |
dc.contributor.author | Kim, Sung Min | - |
dc.contributor.author | Sun, Jong Mu | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Yi, Seong Yoon | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Lee, Sang-Cheol | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Lim, Do Hyoung | - |
dc.contributor.author | Il Lee, Soon | - |
dc.contributor.author | Park, Keon Woo | - |
dc.date.accessioned | 2021-08-11T20:25:49Z | - |
dc.date.available | 2021-08-11T20:25:49Z | - |
dc.date.issued | 2015-04-14 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.issn | 2219-2840 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10723 | - |
dc.description.abstract | AIM: To assess the efficacy and safety of weekly docetaxel plus a fixed-dose rate (FDR) of gemcitabine in metastatic esophageal squamous cell carcinoma (SCC). METHODS: A multi-center, open-label, prospective phase. study was designed. Thirty-three esophageal SCC patients with documented progression after fluoropyrimidine/platinum-based first-line chemotherapy were enrolled and treated with docetaxel 35 mg/m(2) and gemcitabine 1000 mg/m(2) iv at a FDR (10 mg/m(2) per minute) on days 1 and 8. Treatment was repeated every twenty-one days until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was response rate (RR), and secondary endpoints were safety, progression-free survival (PFS) and overall survival (OS). RESULTS: Combination of weekly docetaxel and FDR gemcitabine was well tolerated: the most common treatment-related adverse events were anemia (97%), fatigue (64%) and neutropenia (55%). One patient with multiple lung and lymph node metastases died of respiratory failure after receiving four cycles of chemotherapy, and the possibility of drug-induced pneumonitis could not be completely excluded. Disease control (objective response plus stable disease) in the ITT population was achieved in 88% of patients, and the overall RR was 30% (95% CI: 15%-46%). The median PFS and OS were 4.0 (95% CI: 3.4-4.6) and 8.8 mo (95% CI: 7.8-9.8 mo), respectively. CONCLUSION: A combination of weekly docetaxel and FDR gemcitabine showed promising antitumor activity and tolerability in previously treated, metastatic esophageal SCC. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Baishideng Publishing Group | - |
dc.title | Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.3748/wjg.v21.i14.4268 | - |
dc.identifier.scopusid | 2-s2.0-84927641604 | - |
dc.identifier.wosid | 000352853100020 | - |
dc.identifier.bibliographicCitation | World Journal of Gastroenterology, v.21, no.14, pp 4268 - 4274 | - |
dc.citation.title | World Journal of Gastroenterology | - |
dc.citation.volume | 21 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 4268 | - |
dc.citation.endPage | 4274 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | DOSE-RATE | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | ESCALATION | - |
dc.subject.keywordPlus | SCHEDULES | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Phase II | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Carcinoma, Esophageal neoplasm | - |
dc.subject.keywordAuthor | Squamous cell | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Gemcitabine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.